[1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. doi:10.1056/NEJMra110035910.1056/NEJMra1100359]Search in Google Scholar
[2. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481-490. doi:10.1136/jcp.56.7.48110.1136/jcp.56.7.481]Search in Google Scholar
[3. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973;3(1):1-54. doi:10.1016/0049-0172(73)90034-610.1016/0049-0172(73)90034-6]Search in Google Scholar
[4. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. doi:10.2215/CJN.0578061610.2215/CJN.05780616]Search in Google Scholar
[5. Ward MM. Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995. Arch Intern Med. 2000;160(20):3136–3140. doi:10.1001/archinte.160.20.313610.1001/archinte.160.20.3136]Search in Google Scholar
[6. Tang Y, Zhang W, Zhu M, et al. Lupus nephritis pathology prediction with clinical indices. Sci Rep. 2018;8(1):10231. Published 2018 Jul 6. doi:10.1038/s41598-018-28611-710.1038/s41598-018-28611-7]Search in Google Scholar
[7. Haddon DJ, Diep VK, Price JV, et al. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):162. Published 2015 Jun 17. doi:10.1186/s13075-015-0682-610.1186/s13075-015-0682-6]Search in Google Scholar
[8. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483-495. doi:10.1038/nrneph.2017.8510.1038/nrneph.2017.85]Search in Google Scholar
[9. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 1998;19(4):641-viii. doi:10.1016/s0272-5231(05)70108-810.1016/S0272-5231(05)70108-8]Search in Google Scholar
[10. Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31(3):479-488. doi:10.1016/j.ccm.2010.05.00110.1016/j.ccm.2010.05.00120692540]Search in Google Scholar
[11. Webb WR, Gamsu G. Cavitary pulmonary nodules with systemic lupus erythematosus: differential diagnosis. AJR Am J Roentgenol. 1981;136(1):27-31. doi:10.2214/ajr.136.1.2710.2214/ajr.136.1.276779577]Search in Google Scholar
[12. Ryu JH, Swensen SJ. Cystic and cavitary lung diseases: focal and diffuse. Mayo Clin Proc. 2003;78(6):744-752. doi:10.4065/78.6.74410.4065/78.6.74412934786]Search in Google Scholar
[13. Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev. 2013;12(7):784-791. doi:10.1016/j.autrev.2013.02.00110.1016/j.autrev.2013.02.00123462431]Search in Google Scholar
[14. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78: 736-745.10.1136/annrheumdis-2019-21508930926722]Search in Google Scholar
[15. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi:10.1136/annrheumdis-2013-20513910.1136/annrheumdis-2013-20513924739325]Search in Google Scholar
[16. Sarabi ZS, Chang E, Bobba R et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005;53:60912.10.1002/art.2131416082635]Search in Google Scholar
[17. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:27748210.1002/art.2122416142761]Search in Google Scholar
[18. Bazzan, M., Vaccarino, A. & Marletto, F. Systemic lupus erythematosus and thrombosis. Thrombosis J 13, 16 (2015). doi:10.1186/s12959-015-0043-310.1186/s12959-015-0043-3440732025908929]Search in Google Scholar
[19. Ramirez GA, Efthymiou M, Isenberg DA, Cohen H. Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology (Oxford). 2019;58(6):940-952. doi:10.1093/rheumatology/key30710.1093/rheumatology/key30730380105]Search in Google Scholar
[20. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford). 2003;42(2):230-234. doi:10.1093/rheumatology/keg06910.1093/rheumatology/keg06912595615]Search in Google Scholar
[21. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med. 2000;108(3):198-204. doi:10.1016/s0002-9343(99) 00413-110.1016/S0002-9343(99)00413-1]Search in Google Scholar
[22. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med. 1991;80(291):605-612.]Search in Google Scholar
[23. Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71(6):491-495. doi:10.1038/sj.ki.500211810.1038/sj.ki.500211817264872]Search in Google Scholar
[24. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. doi:10.1002/art.1046110.1002/art.1046112209517]Search in Google Scholar